In the Journals

ACIP updates recommendations for two serogroup B meningococcal vaccines

The Advisory Committee on Immunizations Practices has updated its recommendations to include the implementation of two serogroup B meningococcal vaccines (MenB-4C and MenB-FHbp) for use in at-risk adolescents and young adults aged 10 to 25 years.

“Two serogroup B meningococcal vaccines were recently licensed by the [FDA] and approved for use in persons aged 10 to 25 years,” Temitope Folaranmi, MD, MPH, MBChB, and colleagues wrote. “The evidence supporting the use of [serogroup B meningococcal] vaccines in persons at increased risk for serogroup B meningococcal disease was evaluated … and determined to be type 2 (moderate level of evidence) for use in outbreak settings and type 3 (low level of evidence) for use in persons at increased risk for serogroup B meningococcal disease.”

MenB-4C is a two-dose series vaccine, consisting of three recombinant proteins as well as outer membrane vesicles containing outer membrane protein PorA serosubtype P1.4. Doses of MenB-4C should be administered at least 1 month apart.

MenB-FHbp is a three-dose series vaccine, made up of two purified recombinant FHbp antigens, with one antigen from each FHbp subfamily included. Doses of MenB-FHbp should be administered at 2 and 6 months after the initial dose.

Recommendations were based on analysis of data from 16 clinical trials, as well as a compilation of available peer-reviewed studies and unpublished data on meningococcal disease.

ACIP recommendations for the use of the two serogroup B meningococcal vaccines are restricted to children and young adults aged 10 to 25 years who meet specific at-risk criteria. Criteria include those with anatomic or functional asplenia and microbiologists who are routinely exposed to Neisseria meningitidis. The ACIP also recommends the use of MenB-4C and MenB-FHbp in the instance of an outbreak of serogroup B meningococcal disease.

The researchers said between 97% and 98% of cases of meningococcal disease in the United States are sporadic, but college campuses can pose a high risk for potential meningococcal disease outbreaks. However, MenB-4C and MenB-FHbp are not currently being recommended for routine vaccinations of college students living in residence halls or military recruits.

“Recommendations for broader use of serogroup B meningococcal vaccines in adolescents and college students will be considered separately by the ACIP,” Folaranmi and colleagues wrote. – by David Costill

Disclosure: The researchers report no relevant financial disclosures.

The Advisory Committee on Immunizations Practices has updated its recommendations to include the implementation of two serogroup B meningococcal vaccines (MenB-4C and MenB-FHbp) for use in at-risk adolescents and young adults aged 10 to 25 years.

“Two serogroup B meningococcal vaccines were recently licensed by the [FDA] and approved for use in persons aged 10 to 25 years,” Temitope Folaranmi, MD, MPH, MBChB, and colleagues wrote. “The evidence supporting the use of [serogroup B meningococcal] vaccines in persons at increased risk for serogroup B meningococcal disease was evaluated … and determined to be type 2 (moderate level of evidence) for use in outbreak settings and type 3 (low level of evidence) for use in persons at increased risk for serogroup B meningococcal disease.”

MenB-4C is a two-dose series vaccine, consisting of three recombinant proteins as well as outer membrane vesicles containing outer membrane protein PorA serosubtype P1.4. Doses of MenB-4C should be administered at least 1 month apart.

MenB-FHbp is a three-dose series vaccine, made up of two purified recombinant FHbp antigens, with one antigen from each FHbp subfamily included. Doses of MenB-FHbp should be administered at 2 and 6 months after the initial dose.

Recommendations were based on analysis of data from 16 clinical trials, as well as a compilation of available peer-reviewed studies and unpublished data on meningococcal disease.

ACIP recommendations for the use of the two serogroup B meningococcal vaccines are restricted to children and young adults aged 10 to 25 years who meet specific at-risk criteria. Criteria include those with anatomic or functional asplenia and microbiologists who are routinely exposed to Neisseria meningitidis. The ACIP also recommends the use of MenB-4C and MenB-FHbp in the instance of an outbreak of serogroup B meningococcal disease.

The researchers said between 97% and 98% of cases of meningococcal disease in the United States are sporadic, but college campuses can pose a high risk for potential meningococcal disease outbreaks. However, MenB-4C and MenB-FHbp are not currently being recommended for routine vaccinations of college students living in residence halls or military recruits.

“Recommendations for broader use of serogroup B meningococcal vaccines in adolescents and college students will be considered separately by the ACIP,” Folaranmi and colleagues wrote. – by David Costill

Disclosure: The researchers report no relevant financial disclosures.